Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Durvalumab and Tremelimumab in Advanced Gastric or GEJ Cancer
NCT02340975Phase 2Completed
- Sponsor
- MedImmune
- Start
- Mar 2015
- Primary completion
- Apr 2019
- Modality
- Antibody Conjugates, Engineered Antibody Formats, PD-1/PD-L1 Inhibitors
- Countries
- 6
01
Overview
A Phase 2 trial of durvalumab, tremelimumab in gastric adenocarcinoma, gastroesophageal junction adenocarcinoma, sponsored by MedImmune. Started Mar 2015; status: completed.
02
Drugs
durvalumabtremelimumab
03
Conditions
gastric adenocarcinomagastroesophageal junction adenocarcinoma
Beyond the preview
Go deeper on NCT02340975.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02340975.